MVM Partners, LLC, Director at MDxHealth SA (MDXH), bought 2,202,643 shares at $0.45 ($1000K) on 2026-08-13, disclosed to the SEC on 2026-08-17.
MVM Partners, LLC executed a massive insider purchase of 2.2 million shares at $0.45, representing the largest insider trade in the company's history. This significant capital commitment suggests high conviction in the stock's turnaround potential following recent operational restructuring.
The stock is trading at $3.20, down 39.96% from its 52-week high of $5.33, despite a 12.28% gain over the past year. The price has been relatively flat over the last 30 days, consolidating around the $3 level.
Q2 2026 earnings on August 14, 2026, which reported record sequential revenue growth and a $10.4 million liability elimination. The company is also focused on strategic advancements in prostate cancer diagnostics following the closure of its Plano, Texas laboratory facility.
The stock faces a short interest risk of 2.74% of the float. Additionally, the company reported a Q2 2026 earnings surprise of -50.00% on the bottom line, indicating potential profitability challenges despite revenue beating estimates.
Clearly above the average filing.
| Filing → |
| FNA | SELL | 2025-01-29 | $2.6M | — | Filing → |
| FNA | SELL | 2025-01-27 | $1.0M | — | Filing → |
| FNA | SELL | 2024-12-10 | $803K | — | Filing → |